BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 104 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $990,138 | +1.3% | 139,850 | +0.7% | 0.01% | 0.0% |
Q2 2023 | $977,701 | -4.5% | 138,878 | +13.1% | 0.01% | -11.1% |
Q1 2023 | $1,024,302 | -29.4% | 122,818 | -2.8% | 0.01% | -30.8% |
Q4 2022 | $1,450,762 | +13.4% | 126,373 | +24.5% | 0.01% | +8.3% |
Q3 2022 | $1,279,000 | +9.8% | 101,539 | -7.8% | 0.01% | +9.1% |
Q2 2022 | $1,165,000 | +84.9% | 110,115 | -16.6% | 0.01% | +120.0% |
Q1 2018 | $630,000 | +17.8% | 132,021 | +21.1% | 0.01% | +25.0% |
Q4 2017 | $535,000 | +28.9% | 109,044 | +37.7% | 0.00% | +33.3% |
Q3 2017 | $415,000 | +2.7% | 79,203 | +9.1% | 0.00% | 0.0% |
Q2 2017 | $404,000 | +73.4% | 72,591 | -12.0% | 0.00% | +50.0% |
Q1 2016 | $233,000 | -76.6% | 82,476 | -14.6% | 0.00% | -80.0% |
Q4 2015 | $997,000 | – | 96,610 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DG Capital Management, LLC | 1,186,726 | $4,076,000 | 2.45% |
Sarissa Capital Management LP | 4,861,000 | $16,697,000 | 1.97% |
Ghost Tree Capital, LLC | 1,950,000 | $6,698,000 | 1.94% |
ORACLE INVESTMENT MANAGEMENT INC | 2,525,857 | $8,676,000 | 1.14% |
Eversept Partners, LP | 1,143,211 | $3,926,930 | 0.87% |
DAFNA Capital Management LLC | 749,051 | $2,573,000 | 0.84% |
KNOTT DAVID M | 397,361 | $1,365,000 | 0.80% |
Parkman Healthcare Partners LLC | 800,740 | $2,751,000 | 0.73% |
ACUTA CAPITAL PARTNERS, LLC | 660,000 | $2,267,000 | 0.62% |
Formidable Asset Management, LLC | 578,200 | $1,949,000 | 0.57% |